{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(1)"],"submitter":["Plummer CE"],"funding":["University of Florida","Hhmd, LLC"],"pubmed_abstract":["Equine recurrent uveitis (ERU) is a painful and debilitating autoimmune disease and represents the only spontaneous model of human recurrent uveitis (RU). Despite the efficacy of existing treatments, RU remains a leading cause of visual handicap in horses and humans. Cytokines, which utilize Janus kinase 2 (Jak2) for signaling, drive the inflammatory processes in ERU that promote blindness. Notably, suppressor of cytokine signaling 1 (SOCS1), which naturally limits the activation of Jak2 through binding interactions, is often deficient in autoimmune disease patients. Significantly, we previously showed that topical administration of a SOCS1 peptide mimic (SOCS1-KIR) mitigated induced rodent uveitis. In this pilot study, we test the potential to translate the therapeutic efficacy observed i"],"journal":["Scientific reports"],"pagination":["7177"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9065145"],"repository":["biostudies-literature"],"pubmed_title":["Open label safety and efficacy pilot to study mitigation of equine recurrent uveitis through topical suppressor of cytokine signaling-1 mimetic peptide."],"pmcid":["PMC9065145"],"pubmed_authors":["Polk T","Barr O","Wilhelmy M","Devin K","Clay Smith W","Kolaczkowski BD","Plummer CE","Jones A","Sharma J","Larkin J","Bae SS","Kitchen H"],"additional_accession":[]},"is_claimable":false,"name":"Open label safety and efficacy pilot to study mitigation of equine recurrent uveitis through topical suppressor of cytokine signaling-1 mimetic peptide.","description":"Equine recurrent uveitis (ERU) is a painful and debilitating autoimmune disease and represents the only spontaneous model of human recurrent uveitis (RU). Despite the efficacy of existing treatments, RU remains a leading cause of visual handicap in horses and humans. Cytokines, which utilize Janus kinase 2 (Jak2) for signaling, drive the inflammatory processes in ERU that promote blindness. Notably, suppressor of cytokine signaling 1 (SOCS1), which naturally limits the activation of Jak2 through binding interactions, is often deficient in autoimmune disease patients. Significantly, we previously showed that topical administration of a SOCS1 peptide mimic (SOCS1-KIR) mitigated induced rodent uveitis. In this pilot study, we test the potential to translate the therapeutic efficacy observed i","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-04-08T18:10:39.652Z","creation":"2025-04-04T21:43:34.869Z"},"accession":"S-EPMC9065145","cross_references":{"pubmed":["35505065"],"doi":["10.1038/s41598-022-11338-x"]}}